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Patients with proteinuria, even those with normal glomerular
filtration rate, often present abnormal bone histology. We
evaluated bone histology and the in vitro proliferation of
osteoblasts in samples obtained from 17 proteinuric patients
with primary glomerulopathies. Histomorphometric analysis
of bone biopsies was performed, and bone fragments were
obtained for osteoblast culture, in which we evaluated cell
proliferation. In comparison to controls, patients presented
lower trabecular bone volume (20.9714.5% vs 26.875.9%;
P¼ 0.0008); lower trabecular number (1.770.2/mm vs
2.070.3/mm; P¼ 0.004); and greater trabecular separation
(475.5796.4 lm vs 368.3786.2 lm, P¼ 0.0002). We also
found alterations in bone formation and resorption: lower
osteoid volume (0.970.7% vs 2.071.4%; P¼ 0.0022); lower
osteoid thickness (6.472.8 lm vs 11.573.2 lm; Po0.0001);
less mineralizing surface (4.673.1% vs 13.576.0%;
Po0.0001); lower bone formation rate (0.0370.04 lm3/lm2/
day vs 0.0970.05 lm3/lm2/day; Po0.0001); and greater
osteoclast surface (0.3570.6 vs 0.0570.1%, P¼ 0.0016).
Mean in vitro osteoblast proliferation was lower in patients
than in controls (910.27437.1 vs 2261.071121.0 d.p.m./well,
P¼ 0.0016). Serum concentrations of 25-hydroxyvitamin-D3
correlated negatively with proteinuria and positively with
in vitro osteoblast proliferation. Our results demonstrate that
nonuremic proteinuric glomerulonephritic patients present
bone structure disorder, low bone formation and high bone
resorption, as well as low osteoblast proliferation.
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Vitamin D3 is a leading factor for local and systemic control
of bone remodeling. It affects the activity of both bone-
forming osteoblasts and bone-resorbing osteoclasts by
modulating the synthesis/signaling of growth factors and
cytokines.1 Disorders of the vitamin D system can promote
an uncoupling of bone turnover, with various presentations
of clinical bone disease. In a bone histomorphometry study
involving vitamin D system was shown that, in non-
nephrotic vitamin D-deficient transgenic rats, bone mineral
density decreases and trabecular separation increases.2 In
another study, cultured osteoblasts obtained from osteo-
porotic patients and stimulated with 1,25-dihydroxyvitamin
D3 (1,25(OH)2D3) presented less response than osteoblasts
obtained from normal controls.3
Patients with glomerular diseases and proteinuria present
excessive urinary excretion of various vitamin D metabolites
and their binding proteins.4–6 In addition, even when the
glomerular filtration rate (GFR) is near normal, hypocalce-
mia and intestinal malabsorption of calcium, as well as
reduced serum vitamin D metabolites, are frequently
identified.7–9 Therefore, these patients can experience sig-
nificant biological consequences of bone metabolism and
abnormal bone histology. Some data show normal bone
histology in most such patients,9,10 osteomalacia in 17–56.7%
and even mixed bone disease in 7–50%.11–13 Such discrepant
data might be explained by the inclusion of patients at
different stages of the disease and by the corticosteroid
treatment given to some of the patients studied.
The identification of bone disease is particularly relevant
to patients with nephrotic syndrome, as the incidence of
treatment-resistant and progressive glomerular disease, both
leading causes of chronic kidney disease (CKD), is increasing.
This makes such patients vulnerable to developing uremic
bone disease. Nevertheless, the histological bone alterations
identified in patients with nephrotic syndrome do not
consistently correlate with serum concentrations of divalent
ions or calciotropic hormones. Levels of parathyroid
hormone (PTH) are near normal, despite low serum ionized
calcium levels,12,14 serum phosphorus concentration is
usually normal,12 and calcitriol remains normal in most
patients.12,14 Therefore, the mechanisms that result in altered
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bone metabolism and bone histology in patients with
proteinuric glomerular diseases, before the drop in GFR,
are still unclear despite strong evidence implicating vitamin
D deficiency. Recently, some cytokines and interleukins (ILs)
have been identified as modulators of bone remodeling.15,16
High serum levels of tumor necrosis factor-a, IL-2, IL-4, and
IFN-g have been described in nephrotic patients with active
renal disease, whereas remission is characterized by down-
regulation of these cytokines.17–19 It is well known that the
osteoblast-related interaction between the receptor activator
of nuclear factor-kappaB ligand and its soluble receptor
triggers an osteoclast signaling pathway that induces
osteoclast formation, fusion, activation and survival, leading
to bone resorption and bone loss.20
Freundlich et al.21 showed that serum from patients with
nephrotic syndrome and normal GFR stimulates the activity
of normal human osteoblasts in culture and up regulate their
expression of receptor activator of nuclear factor-kappaB
ligand. There have been no other studies involving the culture
of osteoblasts obtained from patients presenting glomerular
diseases without renal failure. Therefore, the principal aim of
our study was to evaluate the in vitro proliferation of
osteoblasts obtained from patients with nonuremic protein-
uric primary glomerular diseases. Bone histology studies were
also performed.
RESULTS
The group of patients studied consisted of 11 men and six
women. The mean age was 37.479 years (range, 19–55
years). The results of the biochemical analysis are shown in
Table 1. Twelve of the 17 patients presented pronounced
proteinuria (mean, 9.474.0 g/day) and low serum albumin
(mean, 1.770.5 g/dl). The remaining five patients presented
non-nephrotic proteinuria (mean, 2.871.2 g/day) and nor-
mal serum albumin (mean, 3.670.8 g/dl).
In two patients, the concentration of ionized calcium was
below normal. In another two patients and five patients,
respectively, concentrations of 25-hydroxyvitamin D3
(25(OH)D3) and 1,25(OH)2D3 were below normal.
Urinary excretion of calcium was lower than in the general
population22 and correlated negatively with proteinuria
(r¼ 0.52; P¼ 0.03; Figure 1a) and positively with serum
albumin (r¼ 0.5; P¼ 0.02; Figure 1b).
Serum concentrations of 25(OH)D3 were found to
correlate positively with serum albumin (r¼ 0.80;
Po0.0001; Figure 1c) and negatively with proteinuria
(r¼ 0.4; P¼ 0.04; Figure 1d).
Comparing the 12 most proteinuric patients with the five
least proteinuric, we observed that serum levels of 25(OH)D3
were lower in the former than in the latter (13.475.6 ng/ml
vs 30.579.1 ng/ml; P¼ 0.0003).
Bone histomorphometry
In the histomorphometric analysis, comparing mean patient
values to those of controls, we found that bone structure was
altered, the study group patients presenting lower (trabecular
bone volume, 20.9714.5 vs 26.875.9%; P¼ 0.0008),
lower (trabecular number, 1.770.2/mm vs 2.07
0.3/mm; P¼ 0.004) and greater (trabecular separation,
475.5796.4 mm vs 368.3786.2 mm; P¼ 0.0002). In one
patient, the trabecular bone volume was so low (o11%)
that it constituted an increased fracture risk. That patient also
presented the lowest level of serum 25(OH)D3 (5.02 ng/ml).
In addition, most indices of bone formation were
significantly lower in patients compared to controls: (osteoid
volume, 0.970.7% vs 2.071.4%; P¼ 0.0022); (osteoid
thickness, 6.472.8 mm vs 11.573.2 mm; Po0.0001); (miner-
alizing surface, 4.673.1% vs 13.576.0%; Po0.0001); and
bone formation rate (0.0370.04 mm3/mm2/day vs
0.0970.05 mm3/mm2/day; Po0.0001).
As for bone resorption, eroded surface was similar in both
groups, however 41% of the study group patients presented
Table 1 | Biochemical characteristics of the patients studied
(n=17)
Characteristic Mean7s.d. Range Reference values
Serum creatinine (mg/dl) 1.070.2 0.7–1.7 0.5–1.2
GFR (ml/min/1.73 m2) 87.3721.9 56–120 80–120
Serum albumin (g/dl) 2.371.0 0.96–4.5 3.5–5.0
Ionized calcium (mg/dl) 5.070.2 4.6–5.4 4.8–5.4
Serum phosphorus (mg/dl) 4.170.7 3.1–5.9 2.3–4.6
iPTH (pg/ml) 26.3715.6 11.0–62.0 11–60
25(OH)D3 (ng/ml) 18.4710.3 5.0–37.7 8.9–46.7
1,25(OH)2D3 (pg/ml) 32.1717.2 12.2–67.7 15.9–55.6
Proteinuria (g/day) 7.574.5 1.5–17.3 o0.2
Calciuria (mg/kg/day) 0.470.5 0.05–1.7 2.571.2 (22)
GFR, glomerular filtration rate; iPTH, intact parathyroid hormone; 25[OH]D3,
25-hydroxyvitamin D3; 1,25[OH]2D3, 1,25-dihydroxyvitamin D3.
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Figure 1 | Correlations between nephrotic ‘status’ and calciuria,
as well as between nephrotic ‘status’ and serum 25(OH)D3.
(a) Calciuria and proteinuria, (b) calciuria and serum albumin,
(c) 25(OH)D3 and serum albumin, (d) 25(OH)D3 and proteinuria.
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higher eroded surface, compared of controls. Mean osteoclast
surface was significantly higher in the study group (0.3570.6
vs 0.0570.1%, P¼ 0.0016) (Table 2).
The five patients presenting the lowest levels of proteinur-
ia also presented bone alterations in comparison to the
controls: altered bone structure, as evidenced by greater
trabecular separation (434.1727.6 mm vs 368.3786.2 mm)
and lower trabecular bone volume (21.871.7% vs
26.875.9%); and lower bone formation, as evidenced by
lower osteoid volume (8.473.8 mm vs 11.573.2 mm), lower
mineralizing surface (6.573.8% vs 13.576.0%) and lower
bone formation rate (0.0470.03 mm3/mm2/day vs
0.0970.5 mm3/mm2/day). Owing to the limited sample size,
it was not possible to draw statistical comparisons between
these patients with mild proteinuria and controls.
Osteoblast culture
In patient samples, there was less osteoblast proliferation
(910.27437.1 d.p.m./well) than in control samples
(2261.071121.0 d.p.m./well) (P¼ 0.0016; Figure 2).
Although cell proliferation was not found to correlate with
any histomorphometric parameter, it did correlate positively
with serum levels of 25(OH)D3 (r¼ 0.6; P¼ 0.02; Figure 3).
We found no difference between proteinuric patients and
controls in terms of alkaline phosphatase activity in
osteoblasts.
DISCUSSION
The results of the present study demonstrate that nonuremic
proteinuric glomerulonephritis patients present bone struc-
ture disorder, low bone formation, and high bone resorption.
The lower bone formation observed could indicate low
osteoblast function related to the vitamin D insufficiency.
This lower osteoblastic activity, releases osteoclasts to
unregulated activity, resulting in uncoupling of bone
resorption – formation, thereby contributing to the bone
structure disorder.
These results were obtained in nephrotic as well as in non-
nephrotic patients, thereby allowing joint analysis. Our
findings could hardly be attributed to the effects of the
corticosteroids used to treat nephrotic syndrome, as only a
few of the patients (n¼ 5) used corticosteroids, and as those
patients had taken the corticosteroids for a period of only 2–3
months and had discontinued their use 24–84 months before
the bone biopsy. No differences were found between the two
groups in terms of biochemical characteristics or bone
histomorphometry, with or without corticosteroids.
Data in the literature show that bone mineral density, as
measured by densitometry analysis, is decreased in nephrotic
patients.23,24 Although these findings could not be isolated
from corticosteroid or cyclosporine administration, bone
histomorphometry studies of nephrotic patients have shown
increased bone resorption11–13 and decreased mineralizing
surface,11 similar to that seen in patients with CKD. However,
in contrast to CKD patients, nonuremic nephrotic patients
consistently present normal serum phosphorus concentra-
tions, normal serum iPTH concentrations and no metabolic
Table 2 | Histomorphometric parameters
Variable Patients Controls P-value
Structure
BV/TV (%) 20.974.5 26.875.9 0.0008
Tb.Th (mm) 122.8724.0 131.6727.0 NS
Tb.Sp (mm) 475.5796.5 368.3786.2 0.0002
Tb.N (n/mm) 1.770.2 2.070.3 0.0045
Formation
OV/BV (%) 0.970.7 2.071.4 0.0022
Ob.S/BS (%) 2.171.8 1.371.6 NS
O.Th (mm) 6.472.8 11.573.2 o0.0001
OS/BS (%) 8.975.1 11.777.1 NS
MS/BS (%) 4.673.1 13.576.0 o0.0001
MAR (mm/day) 0.770.3 0.6570.12 NS
BFR (mm3/mm2/day) 0.0370.04 0.0970.05 o0.0001
Aj.AR (mm/day) 0.4870.4 0.570.2 NS
MLT (days) 21.7715.6 22.572.5 NS
Resorption
ES/BS (%) 3.173.9 2.071.3 NS
Oc.S/BS (%) 0.3570.6 0.0570.1 0.0016
Aj.AR, adjusted apposition rate; BFR, bone formation rate; BV/TV, trabecular volume;
ES/BS, eroded surface; MAR, mineral apposition rate; MLT, mineralization lag time;
MS/BS, mineralizing surface; NS, nonsignificant; Ob.S/BS, osteoblast surface; Oc.S/BS,
osteoclast surface; OS/BS, osteoid surface; O.Th, osteoid thickness; OV/BV, osteoid
volume; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular
thickness.
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Figure 2 | Osteoblast proliferation measured by incorporation
of thymidine.
0 10 20 30 40
500
1000
1500
r =0.6
P =0.02
25(OH)D3 (ng/dl)
In
co
rp
or
at
io
n 
of
 th
ym
id
in
e
(dp
m/
we
ll)
Figure 3 | Correlation between osteoblast proliferation, as
measured by incorporation of thymidine, and serum levels
of 25(OH)D3.
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acidosis,12 as was seen in our patients. In addition, whereas
serum levels of 25(OH)D3 are frequently reduced during
active nephrotic syndrome as a result of urinary losses,6 those
of calcitriol often remain normal even in patients with
alterations seen in bone densitometry findings.14 Therefore,
none of the principal biochemical characteristics of CKD
bone disease are present in nonuremic nephrotic patients.
Hosogane et al.2 demonstrated that non-nephrotic
vitamin D-deficient rats present lower trabecular number
and greater trabecular separation, similar to the findings of
the present study. The same authors also found an increase in
osteoid tissue, leading to osteomalacia, a situation not
observed in our study. The osteomalacia found in other
studies11,12 might have been related to serum levels of
25(OH)D3 that were lower than those observed in the present
study. Chan et al.25 studied nephrotic rats and found no
osteomalacia, attributing the fact to the short duration of the
nephrotic syndrome.
The calciuria observed in our patients was found to
correlate negatively with proteinuria and positively with
serum albumin. In addition, the calciuria values obtained
were, on average, lower than those seen in a normal Brazilian
population.22 Other authors have presented similar results
regarding calciuria in nephrotic patients.8 It should be borne
in mind that various factors, such as excretion of sodium, as
well as serum levels of iPTH and 1,25(OH)2D3, are involved
in urinary excretion of calcium.8,26 In our patients, calciuria
was not found to correlate with sodium excretion (data not
shown) or serum iPTH. Therefore, the pathogenesis of
hypocalciuria in proteinuric patients remains undefined.
However, it is known that increased 25(OH)D3 induces
hypercalciuria, whereas decreased 25(OH)D3 induces hypo-
calciuria.27,28 In this sense, our findings regarding hypocalci-
uria are consistent with a 25(OH)D3 deficit.
Concerning vitamin D metabolism, urinary losses have
been documented in previous studies.25 In our study, despite
the fact that we did not measure urinary excretion of vitamin
D metabolites, such losses must be present, as evidenced by
the fact that serum concentration of 25(OH)D3 correlated
positively with serum albumin and negatively with protein-
uria. Serum levels of 25(OH)D3 were lower in heavy
proteinuric patients than in non-nephrotic patients.
Concentrations of 1,25(OH)2D3 were normal in 70% of
our patients. The explanation for a finding of normal serum
1,25(OH)2D3 levels in patients with 25(OH)D3 deficiency is
twofold. First, PTH inhibits the enzyme responsible for the
degradation of 1,25(OH)2D3 in inactive metabolites such as
24-hydroxylase.2 Second, as serum concentrations of
25(OH)D3 are 1000 times greater than those of
1,25(OH)2D3, even after drops of up to a third, serum levels
of 25(OH)D3 might be sufficient to maintain normal levels of
1,25(OH)2D3.
2,26 In a recent review, Nordin and Need29
concluded that there is a biphasic relationship between serum
concentrations of 25(OH)D3 and those of 1,25(OH)2D3.
Therefore, as 25(OH)D3 is a precursor of 1,25(OH)2D3,
serum levels of the former correlate positively with those of
the latter. However, when concentrations of 25(OH)D3 are
low, the correlation with 1,25(OH)2D3 becomes a negative
one owing to the fact that serum levels of 1,25(OH)2D3 are
maintained by the effect of PTH.
Concerning serum values for vitamin D, there is still
considerable debate regarding normal values for 25(OH)D3, a
metabolite measured in order to evaluate stores of vitamin
D.30 Thomas et al.31 studied unselected general medical
inpatients and demonstrated that serum concentrations of
25(OH)D3 lower than 15 ng/ml correlated with high serum
concentrations of PTH. Other authors have found that serum
concentrations of 25(OH)D3 above 30 ng/ml were adequate,
showing that lower concentrations favored an increase in
PTH.32 If this higher cutoff point is used, the majority of our
patients presented 25(OH)D3 concentrations that were below
normal, or rather, 25(OH)D3 deficiency, which could explain
the low osteoblastic activity observed.
However, other factors, such as ILs, which are bone
metabolism modulators, must be present. Elevated serum
and urinary activity of various cytokines, including IL-1, IL-
6, IL-2, IL-4, and tumor necrosis factor-a, has been identified
in patients with nephrotic syndrome, particularly during
clinical activity.18 Most of these pro- and anti-osteoclasto-
genic cytokines act primarily through the osteoblasts by
altering levels of receptor activator of nuclear factor-kappaB
ligand and osteoprotegerin, the balance of which determines
osteoclast formation.33 Some cytokines, such as IL-6, also
have direct osteoclast effects.33
Concerning patient osteoblast culture, we have shown
decreased osteoblast proliferation when compared to con-
trols. However, there was no difference between patients and
controls in terms of alkaline phosphatase production. In
addition, it has been shown that osteoblast proliferation
correlates positively with serum concentrations of 25(OH)D3
in age- and gender-matched patients, confirming the
important role that 25(OH)D3 plays in osteoblast prolifera-
tion. Data in the literature concerning osteoblast culture are
scarce and are restricted to CKD patients, among which those
with adynamic bone diseases present decreased osteoblast
proliferation, as would be expected.34,35
Recently, Freundlich et al.21 incubated normal osteoblasts
with sera collected from children with nephrotic syndrome
and observed increases in alkaline phosphatase and receptor
activator of nuclear factor-kappaB ligand in the supernatant,
correlating these findings with an increase in osteoblast
activity. Their data incubating normal osteoblasts with
nephrotic sera is divergent from the osteoblast culture data
obtained for our patients.
In conclusion, the results of our study show that
nonuremic proteinuric glomerulonephritis patients develop
alterations in bone structure, low bone formation and high
bone resorption, and that these changes are unrelated to
corticosteroid use. Patients showed a ‘state’ of vitamin D
deficiency that correlated with protein excretion and low
calcium excretion. Culture of osteoblasts obtained from these
patients showed decreased osteoblast proliferation, which was
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in concordance with the histomorphometric data. In
addition, osteoblast proliferation in culture correlated with
serum levels of 25(OH)D3 from age- and gender-matched
patients.
These disturbances may represent important contributing
factors to the histological bone abnormalities present in
patients with protracted glomerular diseases before any
decline in GFR.
Our study breaks new ground in the use of osteoblast
culture in patients with proteinuria. However, further studies
are needed in order to identify other factors that might be
responsible for the decreased osteoblast proliferation seen
during glomerular proteinuric disease.
MATERIALS AND METHODS
Subjects
Between March 2001 and March 2004, 17 adult patients with
idiopathic glomerulonephritis, all under follow-up treatment at the
Glomerulonephritis Unit of the University of Sa˜o Paulo Hospital das
Clı´nicas, were evaluated. Kidney biopsies revealed that 12 patients
had membranous glomerulonephritis, one had membranoprolifera-
tive glomerulonephritis, three had focal segmental glomerulosclero-
sis, and one had immunoglobulin A nephropathy. Patients were
enrolled in our protocol and submitted to a bone biopsy at 38741
months (8–156 months) after being diagnosed with glomerulopathy.
At the time of their enrollment, all the patients had proteinuria
in excess of 1.5 g/day, GFR greater than 55 ml/min/1.73 m2, and
serum creatinine lower than 1.8 mg/dl. All male patients enrolled
(n¼ 11) were younger than 55 years of age (range, 19–55 years), and
all female patients (n¼ 6) were younger than 40 years (range, 28–45
years).
Patients currently treated with calcium supplements, antic-
onvulsants, oral anticoagulants, or other drugs affecting bone
metabolism, were excluded, as were menopausal women and
patients with thyroid disease. Ten of the patients had never been
treated with corticosteroids or other immunosuppressive drugs. Two
of the seven remaining patients had never used any corticosteroids
except cyclosporin and mycophenolate mofetil for a short period of
time. The other five had taken 1 mg/kg/day of prednisone for 2–3
months, but the prednisone had been discontinued 24–84 months
before the bone biopsy.
During the study thiazide diuretics were on hold for 3 weeks
before the bone biopsy in order to collect serum and urine for
biochemical analysis. All patients were pre-labeled with oral
tetracycline (20 mg/kg/day for 3 days) administered for two separate
periods, 10 days apart. During the protocol, patients were on a free
medication prescription including beta-blockers, calcium channel
blockers, angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, or loop diuretics.
Informed consent was obtained from all patients in advance, and
protocols were approved by the ethical committee of the governing
institution.
Biochemical analysis
The GFR (ml/min/1.73 m2) was estimated with the Modification of
Diet in Renal Disease Study formula as follows: GFR¼ 186 (serum
creatinine1.154) (age0.203) (0.742 if female) (1.21 if black).36
Serum ionized calcium, serum phosphorus and serum albumin were
measured using established methods. Proteinuria and calciuria were
determined in 24-h urine samples. For urinary calcium detection, a
colorimetric assay that detects all urinary calcium (Roche/Hitachi
system with o-cresolphthalein) was utilized. Standard radioimmuno-
assay was used to measure serum 25(OH)D3 and 1,25(OH)2D3.
37 A
PTH-specific radioimmunoassay (ELSA-PTH; CIS Bio International,
Gif-sur-Yvette, France) was used to measure iPTH.
Bone histomorphometry
Biopsy samples of approximately 1.5 cm in length were obtained
from the anterior iliac bone using an electric trephine (Gaulthier
Medical, Rochester, MN, USA) with a 7.5-mm internal diameter.
The patients were under local anesthesia and light sedation.
Undecalcified bone fragments were submitted to the usual
processing and to histological studies.38 Sections (5 mm in
thickness) were stained with toluidine blue for static and structural
parameters using the Osteomeasure software (Osteometrics Inc.,
Atlanta, GA, USA). From the same material, 10-mm unstained slices
were obtained for analysis of dynamic parameters under a
microscope with ultraviolet light. The mean bone area was
38449715723 mm2. The parameters analyzed were in accordance
with the standards set by the American Society of Bone and Mineral
Research.39
The histomorphometric parameters analyzed were as follows:
bone structure, as defined by measuring trabecular bone volume (%),
trabecular number (n/mm), trabecular separation (mm) and
trabecular thickness (mm); bone formation, as defined by measuring
osteoid volume (%), osteoid thickness (mm), osteoid surface (%),
osteoblast surface (%), all of which were measured on stained
sections, as well as mineralizing surface (%), bone formation rate
(mm3/mm2/day), mineral apposition rate (mm/day), adjusted apposi-
tion rate (mm/day), and mineralization lag time (days), all of which
were measured on unstained sections under ultraviolet light; and
bone resorption, as defined by measuring eroded surface (%) and
osteoclast surface (%).
Normal values for the parameters evaluated were determined as
described by Dos Reis et al.40 from our laboratory and by Melsen
et al.41 Gender- and age-matched controls (n¼ 33) were selected
from a large bone histomorphometry database compiled from the
analyses of iliac biopsies of healthy individuals submitted to autopsy
after an early demise. Most were victims of gunshot wounds, knife
wounds, trauma, or traffic accidents and were not known to suffer
from any disease. In addition, none were users of anticonvulsant
drugs, corticosteroids, or any medication known to interfere with
bone metabolism. The mean age was 3675.4 years, and gender
distribution was 1.2 M:1.0 F, both comparable to the study group
data. The controls described by Melsen et al.41 were obtained from
41 volunteers, 12 males aged 23–56 years (mean, 32 years), and 29
females aged 19–53 years (mean, 29 years).
Osteoblast culture
Bone cell populations were isolated from the trabecular bone
surfaces of all biopsies. The trabecular bone was minced into small
(1-mm3) fragments that were washed extensively with phosphate-
buffered saline to remove adherent bone marrow cells. The bone
explants were first cultured in Petri polystyrene plates (Nalge Nunc,
Naperville, IL, USA) with Dulbecco’s Modified Eagle’s Medium,
supplemented with antibiotics (100 mg/ml of penicillin, 100 mg/ml of
streptomycin, and 2.5 mg/ml of amphotericin B) and 10% fetal
bovine serum, then incubated at 371C in a humidified atmosphere
of 5% CO2. Cell outgrowth from the bone surfaces occurred after a
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mean of 13 days. At confluence on the mesh, adherent cells were
dissociated with a combination of 0.2% trypsin and 0.02%
ethylenediaminetetraacetic acid (Instituto Adolfo Lutz, Sa˜o Paulo,
Brazil) and cultured again in 25-cm2 flasks. At each new confluence,
cells were again dissociated, after which they were cultured in
24-well plates for evaluation of cell proliferation and 6-well plates for
determination of total alkaline phosphatase activity. Control group
samples for normal osteoblast culture were obtained from cadaveric
donor organs (n¼ 5; mean age, 38710.6 years; gender distribution,
four M:one F) and were collected in parallel with the study period.
As the phenotypic expression of human bone cells has been
shown to decrease after multiple passages,42 we studied these cells in
the second passage. The cell population obtained from the
trabecular bone surface exhibited an osteoblast phenotype, as
evidenced by the production of alkaline phosphatase and the
mineralization of extracellular matrix.43
Cell proliferation
On day 9 of culture in the 24-well plates, 5 mCi/ml of 3H-thymidine
(Amersham Pharmacia Biotech Brasil Ltda, Sa˜o Paulo, Brazil) were
added to each well, and the culture was continued for an additional
2 h. Subsequently, the thymidine was removed, the cells were washed
twice with phosphate-buffered saline, and DNA was precipitated
with 5% trichloroacetic acid suspended in 300 ml of 0.2 N NaOH and
0.3% sarcosyl. The cell lysates (100 ml) were aliquoted using liquid
scintillation. To incorporate 3H-thymidine into DNA, six aliquots
were measured using a Beckman beta scintillation counter model
LS6200 (Beckman Instruments, Palo Alto, CA, USA).
Alkaline phosphatase activity
At confluence into the 6-well plates, the wells were washed twice
with ice-cold phosphate-buffered saline and scraped, and 500 ml of
iced water were added. The material was sonicated for 30 s and
centrifuged for 30 min at 2000 r.p.m. In the supernatant, alkaline
phosphatase activity was determined on p-nitrophenyl phosphate
substrate, and the results are expressed as IU/l/mg of protein.
Statistical analysis
Except where otherwise indicated, results are expressed as
mean7s.d. For comparisons between groups, either Student’s
unpaired t-test or Mann–Whitney test was used, as appropriate.
Correlations between two variables were determined using the
Pearson coefficient (for normally distributed data) or the Spearman
correlation coefficient (for nonparametric data). Values of Po0.05
were considered statistically significant.
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